SPH7050
SPH7050 is an orally active LANCL2 agonist with a Kd of 3.73 μM. SPH7050 inhibits PGE2 production. SPH7050 attenuates the disease activity index and colonic inflammation in TNBS-induced colitis in mice. SPH7050 can be used for research on inflammatory bowel disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C31H24N8O2
- Molecular Weight:540.57
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
LANCL2 3.73 μM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMDM | IC50 |
0.85 μM
|
Inhibition of PGE2 production in bone marrow-derived macrophages stimulated with lipopolysaccharide (LPS) for 17 hours, measured by ELISA.
Inhibition of PGE2 production in bone marrow-derived macrophages stimulated with lipopolysaccharide (LPS) for 17 hours, measured by ELISA.
|
42623744 |
In Vitro
SPH7050 (0.78-50 μM) binds LANCL2 with a KD of 3.73 μM[1].
SPH7050 inhibits PGE2 production in BMDMs with an IC50 of 0.85 μM[1].
SPH7050 (2-10 μM; 90 min) exhibits extremely low permeability in Caco-2 cells with Papp AP-BL values below or at the 1 × 10-6 cm/s threshold, indicating limited transepithelial transport[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
| Species | Dose | Route | Cmax | Plasma Concentration |
|---|---|---|---|---|
| Mice[1] | 8 mg/kg | p.o. | 6.900 ng/mL | 6.900 (0.5 h) ng/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8-10 weeks old, 18-20 g, TNBS-induced colitis)[1]
-
Dosage:12.5, 25, and 50 mg/kg
-
Administration:p.o.; BID; Day -1 to Day 5
-
Result:Attenuated body weight loss in a dose-dependent manner, with the 50 mg/kg group recovering nearly to baseline by Day 6.
Reduced Disease Activity Index scores dose-dependently, outperforming BT-11 at equal doses and matching mesalazine in efficacy.
Alleviated diarrhea and hematochezia.
Increased colon length and reduced colon weight and weight-to-length ratio relative to vehicle in a dose-dependent manner, with the 50 mg/kg group approaching sham values.
At 50 mg/kg (BID), was superior to BT-11 at the same dose and comparable to mesalazine (100 mg/kg, QD) across all intestinal parameters.
Chemical Information
-
Molecular Weight 540.57
-
Formel C31H24N8O2
-
SMILES
O=C(N[C@H]1[C@]2([H])CN(C(C3=NC(C4=NC5=CC=CC=C5N4)=CC=C3)=O)C[C@]12[H])C6=NC(C7=NC8=CC=CC=C8N7)=CC=C6
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
SPH7050 Related Classifications
HY-189377 Related Classifications
Powered by Bioz